Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. - Wikidata - thesis-toulmin - TriplyDB

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

http://www.wikidata.org/entity/Q34082782

about

Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes Antigen-based immunotherapy for autoimmune disease: current status Risk factors and primary prevention trials for type 1 diabetes Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted ß-cells in diabetic NOD mice Restoring the balance: immunotherapeutic combinations for autoimmune disease 2011 Update: antigen-specific therapy in type 1 diabetes Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting β-cell replication in newly diabetic NOD mice.Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.Mapping I-A(g7) restricted epitopes in murine G6PC2.Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.Efferocytosis promotes suppressive effects on dendritic cells through prostaglandin E2 production in the context of autoimmunity.Treg vaccination in autoimmune type 1 diabetes.Juvenile Diabetes Research Foundation: mission, strategy, and priorities Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice.Antigen targets of type 1 diabetes autoimmunity MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.Can we vaccinate against Type 1 diabetes?Immune interventions to preserve β cell function in type 1 diabetes Primary and secondary prevention of Type 1 diabetes Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention.Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment Trials in type 1 diabetes: Antigen-specific therapies.Progress in immune-based therapies for type 1 diabetes.Targeted immune interventions for type 1 diabetes: not as easy as it looks!Combination immunotherapies for type 1 diabetes mellitus.Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes.Therapies to Preserve β-Cell Function in Type 1 Diabetes.Apportioning Blame: Autoreactive CD4+ and CD8+ T Cells in Type 1 Diabetes.T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases.Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.Selective immunotargeting of diabetogenic CD4 T cells by genetically redirected T cells.GAD65: a prospective vaccine for treating Type 1 diabetes?Role of TGF-β in Self-Peptide Regulation of Autoimmunity.Optimization of current and future therapy for autoimmune diseases.Peripheral Autoimmune Regulator Induces Exhaustion of CD4+ and CD8+ Effector T Cells to Attenuate Autoimmune Diabetes in Non-Obese Diabetic Mice Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model.

P2860

Q26770386-EDE75427-551C-4216-A2B9-C1C6484E26ED Q26852915-346C0E16-50E4-4F2D-B95A-61BAA57F85CE Q27005625-02B61588-2C3F-4E13-A368-159111E5AD7E Q28744642-C6406CF4-CC1A-4E09-A53D-6C96C436BECD Q33555986-3CD7BFE4-0E66-4234-A9BD-4C63FF4FCB31 Q33593629-8A23FF48-AA80-46FF-9C9D-95C771A7C191 Q34077377-95A89BB9-FAE3-4A79-A1E9-DD62D3973280 Q34244112-A73A7CCF-5467-479B-A7C2-0D2970A43CAF Q34415712-EC008CD7-2298-49BA-91E0-03B3DAFDDD42 Q34583970-B981F08E-A5DB-4465-BF86-E0A08831D426 Q34730167-7EEF76BF-B772-4134-9405-D54A83E582E6 Q34957397-EAF2ED39-8534-4487-8775-AF68EFE7B4E6 Q35612407-D321E43C-FAAA-48B2-A76F-9D93C74D2959 Q35665104-BA9AA2B8-A604-4FB9-9028-0EC624D42C3D Q35852999-E269DCB3-5985-4D07-9D63-A9A97BCB7633 Q35891738-1ABB6BE5-7DF3-4185-B578-2D064AE7656F Q35913697-9F0A404C-1A79-4E3F-B917-3A06ABF27E7D Q35976614-C7A34C5B-F884-4933-BD1A-A650A0A7F499 Q36296386-00196462-4210-42FA-9B19-71236A1806F5 Q36520618-333D17EB-E908-4F18-A5AE-721CBF6D6F0F Q36631971-80197794-D8D6-42C8-A6E2-B299EDE2FF9E Q36632019-510C35B8-5BDC-4F84-841C-25FBEB193670 Q36913132-F0A6C5C8-5482-4B41-B25D-53FED52905F8 Q36913149-AC4239EA-8F5F-4902-A30E-B873D272FF02 Q37263111-3A40F899-AD1D-484F-896F-0AF9D4C75186 Q38089387-60E749C2-98FB-4904-9EBA-8E7CCE013E87 Q38097920-1259C8C7-FA65-45BB-B4C0-DA0FF37839A1 Q38225173-708078AF-3039-4ADB-A26F-DB658815B26C Q38358009-55609433-D822-46BB-80C9-87A71D8E2A34 Q38385236-8C4EE1E9-F3EF-47A4-BB8F-C78E1BBEB710 Q38662048-8C91280C-681D-41EF-8AEB-81542F6A4398 Q38771022-D56DA65D-002E-4AFA-A513-4E439976668F Q38826175-A481E925-402E-402B-B60B-FDB3C530A332 Q38828063-358E7569-DA07-4E3E-AB4C-EB0F47E43174 Q38983184-1543A127-3F53-4A64-B469-249960BE8CF0 Q39290175-AA2782B6-A663-4364-A3B0-96625C7427C7 Q39451535-E19C4384-99A0-4FEF-9A86-95FD86895C4E Q39666645-F14D0E8A-D1B7-469A-9AA0-1DA6473EF264 Q41665239-F4C09445-5ACB-4DFF-866C-BF8921944C4B Q53410727-F680B10E-6CBE-4C7C-812F-E3C61984C8B7

P2860

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

http://www.wikidata.org/entity/Q34082782

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@ast

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@en

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@nl

type

label

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@ast

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@en

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@nl

prefLabel

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@ast

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@en

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@nl

P1433

Q34082782-49EED45E-A476-41CF-A662-DB03D8B40111

P1476

Q34082782-3E20D655-9C29-4766-9008-F6DF70D56B64

P2093

Q34082782-DF64A400-CB49-4AE6-BCCB-EC01EC9215B2

P2860

Q34082782-0A95833F-B870-49C8-B582-5E106C59FEFA

Q34082782-130EBA85-960C-477E-9BBA-E9C421147A98

Q34082782-15D9BC8C-E195-4357-AF39-9E61826993F8

Q34082782-25BA55E6-BFBC-4F19-BD9C-1D00AF602E65

Q34082782-28746A57-B89C-4534-A4D8-FC7EEADEFCFB

Q34082782-2B7C231B-6F67-48BE-951D-E389DE933B84

Q34082782-319C4C85-196E-441B-BD75-235C907EA13A

Q34082782-4395519B-2B46-4BE2-BB8F-2F8DDDA04824

Q34082782-5DED628A-35B3-4BB5-A731-F5CD8360BF4C

Q34082782-6A0F4D8C-E1B3-41A8-A32C-4154FD9805C9

P304

Q34082782-536E7915-80D3-40B3-B55F-7EA8420F6EA7

P31

Q34082782-16AA6165-9FB1-4955-BEFA-7D2B99F9FD6C

P356

Q34082782-3BF2669A-0036-457F-93EF-6AA8B6D25119

P407

Q34082782-3E6D57EB-EB04-4748-A32B-CE2625782F2D

P433

Q34082782-D80129AC-CAF1-49E1-91D4-3CDA48A3778F

P478

Q34082782-B4BF3CAC-0CC0-4800-9ABD-05D9E9AFE349

P50

Q34082782-FECC6A09-84B9-428A-959C-9C5BFD2C5C0D

P577

Q34082782-F8D178E0-9760-43EF-A86C-A6B60624C0BA

P5875

Q34082782-07C8BBC7-09F9-4DA8-A9F8-CF69DF90610D

P698

Q34082782-A1080E88-362F-49D4-B20B-8D96687CF2C9

P921

Q34082782-30D7408E-F888-4548-B1A9-EA846F3C9AAE

Q34082782-7F9B0A04-79E5-41C4-9E2C-ED41A50F34A0

P932

Q34082782-B8BC34E1-D1D1-4598-9E05-2175F1BA1BD7

P356

P1433

P1476

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

@en

P2093

Matthias von Herrath

http://www.w3.org/2001/XMLSchema#string

P2860

T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes

Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs

Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23

GAD treatment and insulin secretion in recent-onset type 1 diabetes.

Plasmacytoid dendritic cells mediate oral tolerance

Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.

Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression.

Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis

P304

2087-2093

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB10-0630

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46095334

http://www.w3.org/2001/XMLSchema#string

P698

20805382

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

2927927

http://www.w3.org/2001/XMLSchema#string